Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy

J M Leger, A Ben Younes-Chennoufi, B Chassande, G Davila, P Bouche, N Baumann, P Brunet

Abstract

Intravenous human immune globulin (IVIg) has been proposed for the treatment of various peripheral neuropathies that are considered to be immune-mediated. The results are reported of an open trial conducted in multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. Six cases with multifocal motor neuropathy, selected on clinical and electrophysiological criteria (four of six patients also had significantly high anti-GM1 titres), received IVIg monthly, at doses varying from 1.6 to 2.5 mg/kg, over three to 13 months. The initial response to treatment was dramatic in 3/6 cases (with improvement of at least two grades on the MRC scale in the five more severely affected muscles). The final evaluation showed a good result in 4/6 cases, but the conduction blocks were not significantly reduced. In 13 other cases with polyneuropathy associated with IgM monoclonal gammopathy of unknown significance, IVIg was of benefit, with improvement of at least one grade on the Prineas score, in 4/7 cases previously treated with immunosuppression and 2/3 cases not treated before IVIg. In the last group of four patients with polyneuropathy and IgG monoclonal gammopathy, IVIg was followed by clinical improvement in the two cases with a chronic demyelinating polyneuropathy.

Intravenous human immune globulin (IVIg) has been proposed for the treatment of various peripheral neuropathies that are considered to be immune-mediated: Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy, polyneuropathy associated with IgM monoclonal gammopathy. In this paper, we focus on IVIg treatments in multifocal motor neuropathy and in polyneuropathy associated with monoclonal gammopathy. We review previous reports and give our own results on some studies that have been conducted over the past two years.

Multifocal motor neuropathy

The syndrome of multifocal motor neuropathy (MMN) with persistent conduction blocks was described by Parry and Clarke and by Roth et al. Lewis et al. previously reported a similar syndrome of multifocal sensorimotor neuropathy. These syndromes have been characterised according to clinical, electrophysiological and immunological criteria. They have been discussed as variants of either chronic inflammatory demyelinating polyneuropathy (CIDP) or motor neuron disease.

Clinically, MMN is characterised by progressive weakness with multifocal distribution. Muscular atrophy, cramps, myokymia, fasciculations, preserved reflexes, paucity or complete lack of sensory abnormalities are common features which are similar to those occurring in motor neuron diseases. When more nerves are affected in the course of the disease, these symptoms and signs may become more widespread and mimic those observed in amyotrophic lateral sclerosis. Nevertheless, the following distinctive characteristics define MMN: there is no bulbar involvement and no upper motor neuron signs; motor involvement usually starts in the upper limbs asymetrically, and remain prominent in the arms; careful examination discloses motor involvement and atrophy in individual peripheral nerve territories, so that affected nerves may coexist with normal nerves in the same limb. Tendon reflexes are diminished and frequently absent in the upper limbs. Finally, the course of MMN is usually slowly progressive over years, or even decades, and most of the patients remain ambulatory with various motor handicaps.

Electrodiagnostic studies usually distinguish MMN from MND. Motor nerve conduction studies disclose focal or multifocal conduction blocks confined to motor axons. They may occur at any level, but are commonest in the forearms. The reduction of the amplitude of the evoked motor potential, obtained after proximal stimulation of the motor nerve, is frequently severe (> 80%), and usually accompanied by severe conduction slowing and dispersion of the evoked motor response. These abnormalities of conduction are restricted to short segments of nerve ranging from 3–10 cm in length. Needle electromyography may show fibrillations, fasciculations and myokymia in the affected muscles.

Antibodies directed to GM1 ganglioside in
Table 1  Clinical and laboratory features of patients with MMN

<table>
<thead>
<tr>
<th>Number of cases</th>
<th>Sex/age</th>
<th>Course (years)</th>
<th>Distribution in motor nerves</th>
<th>Total number of infusions</th>
<th>Clinical evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>8</td>
<td>R median &amp; L ulnar + radial</td>
<td>13</td>
<td>dramatic</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>15</td>
<td>R median &amp; L peroneal</td>
<td>8</td>
<td>slight</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>46</td>
<td>R median &amp; L ulnar</td>
<td>8</td>
<td>dramatic</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>22</td>
<td>R median &amp; L peroneal</td>
<td>6</td>
<td>dramatic</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>3</td>
<td>R median &amp; L ulnar</td>
<td>8</td>
<td>mild</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>4</td>
<td>R radial &amp; median</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

N*: Number of infusions corresponding to improvement.

MMN were first reported in 1988 in two cases. Subsequently, the same authors found high titres of these antibodies (80–90%) in a large series of MMN. It was then suggested that antibodies to GM1 ganglioside may play a role in the pathogenesis of MMN. Other studies, however, did not confirm these results: in a French multicentre series of 25 cases, significantly high titres were found in only 41% of cases. Similar results were reported by Lange et al. Conversely, the same antiglycolipid antibodies are found in motor neuron diseases such as ALS, GBS, CIDP and several autoimmune diseases without neurological involvement.

There are relatively few papers on the treatment of MMN. Most of them used prednisone in doses ranging from 25–100 mg/day, with rare improvement and sometimes deterioration. Plasma exchange appears to be of no benefit. High dose intravenous cyclophosphamide has been tried in small studies, and in an open study on 25 cases a beneficial effect was shown in eight cases, accompanied by a reduction in anti-GM1 antibody titres; but conduction blocks did not resolve. IVIg has been tried in numerous studies.

In the series of nine patients reported by Chaudhry et al., strength (measured in the five more affected muscles) improved in all cases three to 10 days after treatment, with improvement peaking at two weeks and lasting for an average of two months; the range of functional improvement varied from dramatic to mild. These authors found a reduction of the degree of motor conduction blocks in 7/8 patients. The serum anti-GM1 antibody titres did not change. Four of the five patients treated by Nobile-Orazio et al. had both increased levels of anti-asialo-GM1 and a good response to IVIg with complete recovery in one case and persistent improvement in three others. This was maintained by periodic two day infusions during six to 12 months. These authors observed a reduction of conduction blocks in most, but not all, motor nerves, and no significant changes in antibody titres. Among the 12 patients with motor neuron syndrome treated with IVIg versus placebo in a double-blind, placebo-controlled study, Azulay et al. found that only the five cases with conduction blocks responded to IVIg treatment.

We treated (preliminary reports in three cases) six patients with multifocal motor neuropathy and conduction blocks. Clinical and electrophysiological data are summarised in Table 1. There were six men aged 34 to 50. The course of the peripheral neuropathy ranged from three to 22 years, but the diagnosis was established on electrophysiological criteria during the last four years. Except for case 6, who had a focal motor involvement of the right radial nerve, all patients had a motor multifocal neuropathy with at least two partial conduction blocks defined with the following criteria: > 50% reduction in both the compound muscle action potentials (CMAP) amplitude and the negative peak area on proximal stimulation compared with the distally stimulated response, with a < 15% change in the negative peak duration. Anti-GM1 ganglioside antibody titres were measured by enzyme-linked immunosorbent assay (ELISA) and immunodetection on thin-layer chromatography (TLC). According to methods previously reported, 4/6 patients (cases 2, 4, 5 and 6) had significantly high titres. All patients received IVIg (Bio-Transfusion) at doses varying from 1-6 to 2-4 mg/kg over a period of two to five days, every month during three to 13 months. For the follow up, the same examiner measured the strength of each patient at baseline and before/after each series of infusions, using both the MRC scale and a functional evaluation (adapted from the Rankin score used for CIDP).

The results are summarised in Table 1. The initial response to treatment was considered to be dramatic in 3/6 patients (cases 1, 3 and 4) with improvement of at least two grades on the MRC scale in the five more affected muscles; it was mild in case 5 and slight in case 2; case 6 who had a focal neuropathy did not respond to treatment and infusions were stopped. In the four responders, we observed a diminution of the response to treatment: a plateau was reached after five to six monthly IVIg infusions in cases 2, 3, 4 and 5, and after 10 months in case 1 (see column N* in table 1,
indicating the number of beneficial series of infusions). The final evaluation (made between six and 13 months, see column table 1) indicated that motor improvement remained unchanged in four cases despite repeated IVIg infusions (excellent in cases 1 and 4, mild in case 5 and slight in case 3). In case 2, we observed a subsequent motor deterioration. Electrophysiological study failed to find a significant reduction of the degree of conduction block in all cases studied. This point has been a source of discussion in previous papers. Chaudhry et al16 and Nobile-Orazio et al17 found a significant reduction of conduction block, but as was found with our cases other authors did not.18 This lack of correlation may be due to persistent differential dispersion and phase cancellation in affected nerves. In addition, some blocks may be located in very proximal segments of motor nerves and could not be measured by conventional electrodiagnostic studies.

Polineuropathy associated with IgM monoclonal gammopathy
Polineuropathy associated with Waldenström's disease was first recognised 30 years ago.14 The concept of "monoclonal gammopathy of unknown significance" (MGUS) is more recent. Smith et al19 reported the first large series of polineuropathies associated with an IgM-MGUS. The main point was that these polineuropathies seem to constitute a well-characterised group with clinical, electrophysiological and pathological features indicating a demyelinating process.20 In addition Latov et al21 showed that the pathological IgM binds to MAG (myelin-associated glycoprotein), a protein which is present in human peripheral nerve myelin. From this date, numerous other IgM antibody activities directed to other myelin nerve antigens have been widely described.22,23 Anti-MAG antibody activity and any glycolipid antibody activity (mainly directed to sulphoglucuronyl glycolipids (SGGL)) which correspond to the same oligosaccharide epitope as MAG) seem to be highly correlated with the demyelinating process. In our series of 40 cases,27 in 33 cases there was an excellent correlation between electrophysiological features of demyelinating polineuropathy, and either anti-MAG activity (26 cases, p < 0·0001), or anti-SGGL activity (26 cases, p < 0·01). The course is usually slowly progressive and some cases remain stable for years; but in most, sensorimotor disturbances worsen and a distal motor involvement may occur, leading to a disability that is probably underestimated. In our series,27 a third of patients were unable to walk without support and became ADL dependent.

Many open trials with immunosuppressive drugs (chlorambucil: 28; cyclophosphamide: 29) or plasma exchange (PE)30 have been widely conducted. We reported the results of a randomised control study31 conducted on 44 patients with deteriorating polineuropathy and IgM monoclonal gammopathy (mainly MGUS). Patients were treated with either chlorambucil alone for one year, or chlorambucil in combination with 15 PE sessions within the first four months. We found that one year of treatment with chlorambucil was followed by clinical improvement of the peripheral neuropathy in only one third of patients. Plasma exchange did not seem to bring any additional effect when comparing the two groups.

The use of IVIg was proposed in 199032 in the treatment of polineuropathies associated with IgM monoclonal gammopathy. We conducted an open study in 13 cases of deteriorating IgM-associated polineuropathy, with IVIg (Bio Transfusion) 2 g/kg repeated in intervals of four weeks, for six months to two years. In three cases IVIg was stopped because of recurrent allergic rashes. Seven cases had previously been treated by immunosuppressive drugs without any beneficial effect; the characteristics of these patients are summarised in table 2. We observed in 4/7 cases an improvement of at least 1 grade at Prineas score (see table 2). The electrophysiological features, the IgM serum level and the antibody activity remained unchanged. The three last cases had no previous treatment and were treated with IVIg for five to 12 months: a significant improvement of the Prineas score was observed in two cases. Further controlled studies are necessary to discover whether IVIg can be considered as a treatment of poly-

Table 2 Polineuropathies associated with IgM-MG: seven cases previously treated before IVIg

<table>
<thead>
<tr>
<th>Number of cases</th>
<th>Sex/age</th>
<th>Course (years)</th>
<th>Treatments before IVIg</th>
<th>IgM antibody activity</th>
<th>IgM serum level (g/l)</th>
<th>Number of IVIg infusions</th>
<th>Neurological score (Prineas)</th>
<th>Before treatment</th>
<th>After treatment</th>
</tr>
</thead>
</table>
neuropathies associated with IgM monoclonal gammapathy.

Polyneuropathy associated with IgG monoclonal gammapathy

Polyneuropathies associated with IgG monoclonal gammapathy may be seen in multiple myeloma 28 or solitary plasmacytoma, sometimes associated with a POEMS syndrome. 29 Polyneuropathies associated with IgG-MGUS are heterogenous. They may present as sensorimotor distal polyneuropathies with electrophysiological and pathological features consistent with an axonopathy, a myelinopathy or a “mixed” peripheral neuropathy. No specific antibody activity has been demonstrated in these polyneuropathies.

Several treatments have been proposed, mainly with steroids, 30 or plasma exchange. 31 Recently, Dyck et al. 32 conducted a double blind randomised trial with PE versus sham exchanges, and observed a significant improvement in polyneuropathies associated with IgG monoclonal gammapathy. We treated four patients with IgG-MGUS associated polyneuropathy, with IV Ig given monthly at 2 g/kg, from three months to three years. We observed no response in two cases with axonal polyneuropathy, but a significant clinical improvement in two cases who had a chronic demyelinating polyneuropathy; one of these cases initially had a good response but returned to baseline despite periodic four day then two day IV Ig infusions over a period of three years.


Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy.

J M Leger, A B Younes-Chennoufi, B Chassande, G Davila, P Bouche, N Baumann and P Brunet

*J Neurol Neurosurg Psychiatry* 1994 57: 46-49
doi: 10.1136/lnnp.57.Suppl.46